7 Meta ads from finance newsletters that lead with testimonial, longest-running first. The longest has been live 10 days, which usually means it pays back. How we classify ads.
The "Great Tech Split" of 2026
One company to crush Tesla… another to rival Netflix… a third to upset Amazon? 60-year Wall Street legend Marc Chaikin says these stocks are poised to overtake tech's current blue chips in a move that could completely reorder the top of the market. He's giving away names, tickers and trade ideas free — watch now.
in 2 ads at onceCTA: Ver detalhes3 variants
The "Great Tech Split" of 2026
One company to crush Tesla… another to rival Netflix… a third to upset Oracle? 60-year Wall Street legend Marc Chaikin says these stocks are poised to overtake tech's current blue chips in a move that could completely reorder the top of the market. He's giving away names, tickers and trade ideas free — watch now.
in 2 ads at onceCTA: Ver detalhes2 variants
"Summer of Surge" for These Three Stocks
One company to crush Tesla… another to rival Netflix… a third to upset Oracle? 60-year Wall Street legend Marc Chaikin says these stocks are poised to overtake tech's current blue chips in a move that could completely reorder the top of the market. He's giving away names, tickers and trade ideas free — watch now.
single adCTA: Ver detalhes2 variants
"Summer of Surge" for These Three Stocks
One company to crush Tesla… another to rival Netflix… a third to upset Amazon? 60-year Wall Street legend Marc Chaikin says these stocks are poised to overtake tech's current blue chips in a move that could completely reorder the top of the market. He's giving away names, tickers and trade ideas free — watch now.
single adCTA: Ver detalhes3 variants
The "Great Tech Split" of 2026
One company to crush Tesla… another to rival Netflix… a third to upset Amazon? 60-year Wall Street legend Marc Chaikin says these stocks are poised to overtake tech's current blue chips in a move that could completely reorder the top of the market. He's giving away names, tickers and trade ideas free — watch now.
single adCTA: Ver detalhes3 variants
TipRanks | Stock Market Research, Analysis, News & Investing Tools
$RDHL Deal Alert RedHill Biopharma is selling its Talicia H. pylori drug business to Apotex Health Corp in an $18 million upfront deal - with up to $35 million more in potential milestone payments on the table. Talicia treats H. pylori, a bacterial infection linked to stomach cancer and ulcers that affects roughly 35% of the U.S. population. RedHill held a 70% stake in the drug; Apotex already owned the remaining 30% through its earlier acquisition of Cumberland Pharmaceutical's branded business. For RedHill, this isn't just a sale - it's a strategic pivot. The company says the deal strengthens its balance sheet and funds the next phase of expanding its gastrointestinal commercial portfolio, as it works toward profitability. Read more: https://www.tipranks.com/news/redhill-sells-its-talicia-h-pylori-drug-business-to-apotex-in-18m-deal-to-fuel-growth Not financial advice. Always do your own research. #RedHill #RDHL #Biotech #Pharma #StockNews #TipRanks #MergersAndAcquisitions
single adCTA: Saber mais2 variants
TipRanks | Stock Market Research, Analysis, News & Investing Tools
$RDHL Deal Alert RedHill Biopharma is selling its Talicia H. pylori drug business to Apotex Health Corp in an $18 million upfront deal - with up to $35 million more in potential milestone payments on the table. Talicia treats H. pylori, a bacterial infection linked to stomach cancer and ulcers that affects roughly 35% of the U.S. population. RedHill held a 70% stake in the drug; Apotex already owned the remaining 30% through its earlier acquisition of Cumberland Pharmaceutical's branded business. For RedHill, this isn't just a sale - it's a strategic pivot. The company says the deal strengthens its balance sheet and funds the next phase of expanding its gastrointestinal commercial portfolio, as it works toward profitability. Read more: https://www.tipranks.com/news/redhill-sells-its-talicia-h-pylori-drug-business-to-apotex-in-18m-deal-to-fuel-growth Not financial advice. Always do your own research. #RedHill #RDHL #Biotech #Pharma #StockNews #TipRanks #MergersAndAcquisitions
single adCTA: Saber mais2 variants
See which ones lasted, where they send the click, and what offer they lead with.
